Hepatic Hemangiosarcoma: An Absolute Contraindication to Liver Transplantation-The European Liver Transplant Registry Experience.

1 Starzl Abdominal Transplant Unit, University Hospitals St. Luc, Brussels, Belgium. 2 Centre Hépatobiliaire Paul Brousse, Paris, France. 3 Liver Unit, Queen Elizabeth Hospital, Birmingham, UK. 4 Department of Transplantation, Karolinska University Hospital, Huddinge, Stockholm, Sweden. 5 Department of Hepatobiliary Surgery and Liver Transplantation, UMC Groningen, the Netherlands. 6 Department of General and Transplantation Surgery, University Hospital of Essen, Essen, Germany. 7The Royal Free Sheimla Sherlock Liver Centre and University Department of Surgery, Royal Free Hospital and UCL, London, UK. 8 Department of Visceral and Transplantation Surgery, Inselspital, Bern, Switzerland. 9 Department of Lung and Liver Transplantation, Ospedali Riuniti, Bergamo, Italy. 10 Universitätsklinik, Innsbruck, Austria. 11 Department of Hepatobiliary and Liver Transplantation Surgery, Hospital Clinic I Provincial, Barcelona, Spain. 12 Service Chirurgie Digestive et Transplantations, CHU, Univ Nord-de-France, Lille, France. 13 ELT Registry, Paris, France. 14 Currently, Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, NC. 15 Address correspondence to: Prof. Jan Lerut, M.D., Ph.D., F.A.C.S., Starzl Abdominal Transplant Unit, University Hospitals St. Luc, Department of Abdominal Surgery and Transplantation, Université catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Transplantation (Impact Factor: 3.83). 01/2013; 95(6). DOI: 10.1097/TP.0b013e318281b902
Source: PubMed


Liver transplantation (LT) is performed for hemangiosarcoma (HAS) despite disappointing results.

Retrospective study of 14 males and 8 females reported to the European Liver Transplant Registry. In view of the difficult differential diagnosis between HAS and hemangioendothelioma (HE), the study was deliberately restricted to the period 1986 to 2004 to allow comparison of clinical and biochemical behavior of HAS and HE liver recipients transplanted during the same time period.

Clinical signs, symptoms, and biochemical parameters differed significantly. Pre-LT diagnosis of HAS was made in only 5 of 16 (31%) biopsied patients. HE (7 patients) and hepatocellular cancer (2 patients) were confounding diagnoses leading to LT. Extrahepatic disease was present at time of LT in 4 (19%) patients. Giant invalidating tumor (5 HAS, 1 with Budd-Chiari syndrome [BCS], and 10 supposed epithelioid hemangioendothelioma, 1 with BCS), acute BCS of unknown origin (2 patients), chronic liver failure (4 patients), and solitary hepatocellular cancer (1 patient) were the main indications for LT. Overall survival was 7.2±2.6 months; no patient survived after 23 months. Recurrence was diagnosed after 5.0±2.6 months. Seventeen (77.2%) patients died of tumor recurrence, and the remaining 5 patients died of early infections.

HAS is an absolute contraindication to LT due to the poor outcome. When dealing with the difficult differential diagnosis between HAS and HE, futile LT can be avoided by taking into consideration their distinct clinical and biochemical behaviors as well as a 6-month wait-list observation period. This time period enables the evaluation of HAS disease progression without compromising prognosis of HE patients, thereby allowing to avoid organ wastage.

1 Follower
39 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiosarcomas account for a mere 2-3% of adult soft tissue sarcomas, with an overall poor outcome. Depending on the primary site, angiosarcomas have distinct prognosis. Primary hepatic angiosarcomas (PHA) are much rare tumors, with worse prognosis compared with other angiosarcomas. PHA is reported associated with vinyl chloride, but the majority of patients were still with unknown etiology. As PHA lack specific symptoms, signs or images, pathological diagnosis is necessary. The review summarizes 25 articles published from January 2000 to December 2012 including 64 cases of PHA with detailed information. Survival curves are estimated using the Kaplan-Meier method by SPSS 21.0. We find that median survival time is 5 months; local excision alone or combination with adjuvant therapy is the optimal choice, with median survival time of 17 months. In addition, liver transplantation is abandoned for high recurrence rate; emergent transcatheter arterial embolization (TAE) is thought to be an efficient method for controlling intra-abdominal bleeding; and transcatheter arterial chemoembolization (TACE) and chemotherapy may be helpful for improving survival.
    Journal of Gastroenterology and Hepatology 12/2013; 29(5). DOI:10.1111/jgh.12506 · 3.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Improvements in the medical and pharmacological management of liver transplantation (LT) recipients have led to a better long-term outcome and extension of the indications for this procedure. Liver tumors are relevant to LT; however, the use of LT to treat malignancies remains a debated issue because the high risk of recurrence. In this review we considered LT for hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), liver metastases (LM) and other rare tumors. We reviewed the literature, focusing on the past 10 years. The highly selected Milan criteria of LT for HCC (single nodule < 5 cm or up to 3 nodules < 3 cm) have been recently extended by a group from the University of S. Francisco (1 lesion < 6.5 cm or up to 3 lesions < 4.5 cm) with satisfying results in terms of recurrence-free survival and the "up-to-seven criteria". Moreover, using these criteria, other transplant groups have recently developed downstaging protocols, including surgical or loco-regional treatments of HCC, which have increased the post-operative survival of recipients. CCA may be treated by LT in patients who cannot undergo liver resection because of underlying liver disease or for anatomical technical challenges. A well-defined protocol of chemoirradiation and staging laparotomy before LT has been developed by the Mayo Clinic, which has resulted in long term disease-free survival comparable to other indications. LT for LM has also been investigated by multicenter studies. It offers a real benefit for metastases from neuroendocrine tumors that are well differentiated and when a major extrahepatic resection is not required. If LT is an option in these selected cases, liver metastases from colorectal cancer is still a borderline indication because data concerning the disease-free survival are still lacking. Hepatoblastoma and hemangioendothelioma represent rare primary tumors for which LT is often the only possible and effective cure because of the frequent multifocal, intrahepatic nature of the disease. LT is a very promising procedure for both primary and secondary liver malignancies; however, it needs an accurate evaluation of the costs and benefits for each indication to balance the chances of cure with actual organ availability.
    World Journal of Gastroenterology 05/2014; 20(18):5345-5352. DOI:10.3748/wjg.v20.i18.5345 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significant achievements in the organ replacement approach for malignancies over the last 2 decades opened new horizons, and the age of "Transplant Oncology" has dawned. The indications of liver transplantation for malignancies have been carefully expanded by a strict patient selection to assure comparable outcomes with non-malignant diseases. Currently, the Milan criteria, gold standard for hepatocellular carcinoma, are being challenged by high-volume centers worldwide. Neoadjuvant chemoradiation therapy and liver transplantation for unresectable hilar cholangiocarcinoma has been successful in specialized institutions. For other primary and metastatic liver tumors, clinical evidence to establish standardized criteria is lacking. Intestinal and multivisceral transplantation is an option for low-grade neoplasms deemed unresectable by conventional surgery. However, the procedure itself is in the adolescent stage. Solid organ transplantation for malignancies inevitably suffers from "triple distress," i.e., oncological, immunological, and technical. Organ bioengineering and regenerative medicine should serve as the "triple threat" therapy and revolutionize "Transplant Oncology."
    Organogenesis 05/2014; 10(2). DOI:10.4161/org.29245 · 2.80 Impact Factor
Show more